Second Quarter Revenues of $452.1 million,
down 3.4% over prior year period; up 4.7% on Constant Currency
Basis
Second Quarter GAAP Diluted EPS of $0.93,
down 10.6% over the prior year period
Second Quarter Adjusted Diluted EPS of
$1.42, down 6.0%, reflecting unfavorable impact from foreign
exchange of approximately 20%
2015 Constant Currency Revenue and Adjusted
Diluted EPS Guidance Reaffirmed
Teleflex Incorporated (NYSE: TFX) (the “Company”) today
announced financial results for the second quarter ended June 28,
2015.
Second quarter net revenues were $452.1 million, a decrease of
3.4% over the second quarter 2014. Excluding the impact of foreign
currency fluctuations, second quarter net revenues increased 4.7%
over the year ago quarter.
Second quarter GAAP diluted earnings per share from continuing
operations decreased 10.6% to $0.93, as compared to $1.04 in the
prior year period. Second quarter adjusted diluted earnings per
share from continuing operations decreased 6.0% to $1.42, compared
to $1.51 in the prior year period.
“During the second quarter of 2015, Teleflex continued its solid
operating performance, building upon the results realized earlier
this year,” said Benson Smith, Chairman, President and Chief
Executive Officer. “Once again, we generated mid-single digit
constant currency revenue growth and achieved adjusted earnings per
share ahead of our previous expectations. In fact, adjusted
earnings per share would have been higher during the second quarter
of 2015 had it not been for foreign exchange, which impacted
results negatively by approximately 20% as compared to the second
quarter of 2014."
Added Smith, "In addition, during the second quarter, we
continued to make progress in our strategic initiatives, including
the acquisition of a distribution partner of Teleflex's Surgical
products in Australia, the acquisition of exclusive North American
distribution rights to the AutoFuser® range of disposable pain
control pumps, and the receipt of FDA market clearance for its
Arrow® Endurance™ Extended Dwell Peripheral Catheter System. Based
on our results for the first half of 2015, Teleflex remains on
target to achieve our previously provided constant currency revenue
growth and adjusted diluted earnings per share guidance for
2015.”
SECOND QUARTER NET REVENUE BY SEGMENT AND GEOGRAPHY
Effective April 1, 2015, the Company reorganized certain of its
businesses to better leverage the Company's resources. As a result,
the Company realigned its operating segments. Specifically, the
Company's Anesthesia/Respiratory North America operating segment
was divided into two operating segments, Anesthesia North America
and Respiratory North America. Additionally, the businesses
comprising the Company's former Specialty operating segment (which
was not a reportable segment and, therefore, was included in the
"All other" category in the Company's presentation of segment
information) were transferred to the Anesthesia North America,
Vascular North America and Respiratory North America operating
segments.
As a result of the operating segment changes described above,
the Company has the following six reportable operating segments:
Vascular North America, Anesthesia North America, Surgical North
America, EMEA, Asia and OEM. In connection with its presentation of
segment information, the Company will continue to present certain
operating segments, including, among others, the Respiratory North
America operating segment, in the "All other" category. All prior
comparative periods have been restated to reflect these
changes.
Vascular North America second quarter net revenues were $81.2
million, an increase of 5.1% compared to the second quarter 2014.
Excluding the impact of foreign currency fluctuations, second
quarter net revenues increased 5.6% compared to the year ago
quarter. The increase in constant currency revenue was largely due
to higher sales volume of existing products, somewhat offset by a
decrease in new product sales.
Surgical North America second quarter net revenues were $40.5
million, an increase of 6.7% compared to the second quarter 2014.
Excluding the impact of foreign currency fluctuations, second
quarter net revenues increased 7.8% compared to the year ago
quarter. The increase in constant currency revenue was largely due
to new product sales, MiniLap product sales and price
increases.
Anesthesia North America second quarter net revenues were $45.6
million, a decrease of 0.3% compared to the second quarter 2014.
Excluding the impact of foreign currency fluctuations, second
quarter net revenues increased 0.2% compared to the year ago
quarter. The increase in constant currency revenue was largely due
to new product sales, somewhat offset by lower sales volume of
existing products and price decreases.
EMEA second quarter net revenues were $129.1 million, a decrease
of 16.5% compared to the second quarter 2014. Excluding the impact
of foreign currency fluctuations, second quarter net revenues
increased 1.7% compared to the year ago quarter. The increase in
constant currency revenue was largely due to higher sales volume of
existing products and an increase in new product sales, somewhat
offset by price decreases.
Asia second quarter net revenues were $62.1 million, a decrease
of 0.8% compared to the second quarter 2014. Excluding the impact
of foreign currency fluctuations, second quarter net revenues
increased 9.4% compared to the year ago quarter. The increase in
constant currency revenue was largely due to price increases,
increased sales volume of existing products, product sales
resulting from the acquisition of Human Medics Co. Ltd., and an
increase in new product sales.
OEM and Development Services (“OEM”) second quarter net revenues
were $37.9 million, an increase of 3.6% compared to the second
quarter 2014. Excluding the impact of foreign currency
fluctuations, second quarter net revenues increased 7.5% compared
to the year ago quarter. The increase in constant currency revenue
was largely due to higher sales volume of existing products and an
increase in new product sales.
Three Months Ended % Increase/
(Decrease) June 28, 2015 June 29, 2014
ConstantCurrency
ForeignCurrency
TotalChange
(Dollars in millions) Vascular North America $ 81.2 $ 77.2 5.6 %
(0.5 %) 5.1 % Surgical North America 40.5 38.0 7.8 % (1.1 %) 6.7 %
Anesthesia North America 45.6 45.7 0.2 % (0.5 %) (0.3 %) EMEA 129.1
154.7 1.7 % (18.2 %) (16.5 %) Asia 62.1 62.5 9.4 % (10.2 %) (0.8 %)
OEM 37.9 36.6 7.5 % (3.9 %) 3.6 % All Other 55.7 53.4
6.0 % (1.7 %) 4.3 % Total $ 452.1 $ 468.1 4.7 % (8.1 %) (3.4 %)
OTHER FINANCIAL HIGHLIGHTS AND KEY PERFORMANCE
METRICS
Depreciation expense, amortization of intangible assets and
deferred financing costs for the first six months of 2015
aggregated $60.6 million compared to $63.8 million for the prior
year period.
Cash and cash equivalents at June 28, 2015 were $325.0 million
compared to $303.2 million at December 31, 2014.
Net accounts receivable at June 28, 2015 were $286.4 million
compared to $273.7 million at December 31, 2014.
Net inventories at June 28, 2015 were $347.1 million compared to
$335.6 million at December 31, 2014.
Net debt obligations at June 28, 2015 were $816.7 million
compared to $801.4 million at December 31, 2014.
2015 OUTLOOK
The Company continues to estimate that constant currency revenue
growth will be between 4% and 6%. On a GAAP basis, revenues are
expected to be flat to down 2% versus the prior year due to the
unfavorable impact of foreign currency fluctuations.
The Company also continues to estimate that adjusted diluted
earnings per share from continuing operations will be between $6.10
and $6.35, representing an increase of 6.3% to 10.6% over the prior
year. Consistent with our previous expectations, we anticipate that
foreign currency fluctuations will negatively impact adjusted
earnings per share in 2015 by approximately 15%. The Company has
updated its full year 2015 GAAP diluted earnings per share from
continuing operations range from $4.13 to $4.28 to a range of $4.23
to $4.38, reflecting an expected reduction in 2015 forecasted
restructuring, impairment charges and special items, net of
tax.
FORECASTED 2015 CONSTANT CURRENCY
REVENUE GROWTH RECONCILIATION
Low High Forecasted 2015 GAAP
revenue growth (2 %)
-
Estimated impact of foreign currency fluctuations 6 %
6
% Forecasted 2015 constant currency revenue growth 4
% 6 %
FORECASTED 2015 ADJUSTED EARNINGS PER
SHARE RECONCILIATION
Low High Diluted earnings per
share attributable to common shareholders $ 4.23 $ 4.38
Restructuring, impairment charges and special items, net of tax $
0.80 $ 0.85 Intangible amortization expense, net of tax $
0.90 $ 0.95 Amortization of debt discount on convertible
notes, net of tax $ 0.17 $ 0.17
Adjusted diluted earnings per share $ 6.10 $ 6.35
CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION
As previously announced, Teleflex will comment on its financial
results on a conference call to be held today at 8:00 a.m. (ET).
The call will be available live and archived on the company’s
website at www.teleflex.com and the accompanying
presentation will be posted prior to the call. An audio replay will
be available until August 6, 2015 at 11:59pm (ET), by calling
888-286-8010 (U.S./Canada) or 617-801-6888 (International),
Passcode: 52181612.
ADDITIONAL NOTES
Constant currency revenue growth excludes the impact of
translating the results of international subsidiaries at different
currency exchange rates from period to period.
In the discussion of segment results, "new products" refers to
products we have sold for 36 months or less, and "existing
products" refers to products we have sold for more than 36
months.
Certain financial information is presented on a rounded basis,
which may cause minor differences.
Segment results and commentary exclude the impact of
discontinued operations.
NOTES ON NON-GAAP FINANCIAL MEASURES
This press release includes certain non-GAAP financial measures,
which include:
Adjusted diluted earnings per share. This measure excludes,
depending on the period presented (i) the effect of charges
associated with our restructuring programs; (ii) losses and other
charges, including acquisition and integration costs, charges
related to facility consolidations, charges related to contingent
consideration liabilities and charges related to a litigation
verdict against the Company with respect to a non-operating joint
venture, net of specified reversals, including a reversal of
liabilities related to certain contingent consideration
arrangements; (iii) amortization of the debt discount on the
Company’s convertible notes; (iv) intangible amortization expense;
(v) loss on extinguishment of debt; and (vi) tax benefits resulting
from the resolution of, or expiration of the statute of limitations
with respect to, prior years’ tax matters. In addition, the
calculation of diluted shares within adjusted earnings per share
gives effect to the anti-dilutive impact of the Company’s
convertible note hedge agreements, which reduce the potential
economic dilution that otherwise would occur upon conversion of the
Company’s senior subordinated convertible notes (under GAAP, the
anti-dilutive impact of the convertible note hedge agreements is
not reflected in diluted shares).
Constant currency revenue growth. This measure excludes the
impact of translating the results of international subsidiaries at
different currency exchange rates from period to period.
Management believes these measures are useful to investors
because they eliminate items that do not reflect Teleflex’s
day-to-day operations. In addition, management believes that the
calculation of non-GAAP diluted shares is useful to investors
because it provides insight into the offsetting economic effect of
the convertible note hedge against conversions of the convertible
notes. Management uses these financial measures for internal
managerial purposes, when publicly providing guidance on possible
future results, and to assist in our evaluation of period-to-period
comparisons. These financial measures are presented in addition to
results presented in accordance with generally accepted accounting
principles (“GAAP”) and should not be relied upon as a substitute
for GAAP financial measures. Tables reconciling historical adjusted
diluted earnings per share to historical GAAP earnings per share
are set forth below. Tables reconciling constant currency net
revenues to GAAP net revenues and reconciling forecasted non-GAAP
measures to the most directly comparable forecasted GAAP measures
are set forth above.
RECONCILIATION
OF CONSOLIDATED STATEMENT OF INCOME ITEMS Dollars in
millions, except per share amounts Quarter Ended –
June 28, 2015
Cost ofgoodssold
Selling,general
andadministrativeexpenses
Researchanddevelopmentexpenses
Restructuringand
otherimpairmentcharges
Interestexpense,net
Loss onextinguishmentof
debt, net
Incometaxes
Net
income(loss)attributableto
commonshareholdersfromcontinuingoperations
Dilutedearnings
pershareavailable
tocommonshareholders
Shares
usedincalculationof GAAP
andadjustedearnings pershare
GAAP Basis $218.8 $142.2 $13.4 $0.6 $16.1 $10.5 $5.3 $44.8 $0.93
48,081 Adjustments Restructuring and other impairment charges — — —
0.6 — — 0.2 0.4 $0.01 — Losses and other charges (A) 3.1 (3.4 ) — —
— — 0.6 (0.9 ) ($0.03 ) — Amortization of debt discount on
convertible notes — — — — 3.3 — 1.2 2.1 $0.04 — Intangible
amortization expense — 15.1 — — — — 4.1 10.9 $0.23 — Loss on
extinguishment of debt, net — — — — — 10.5 3.8 6.6 $0.14 — Tax
adjustment (B) — — — — — — 0.3 (0.3 ) ($0.01 ) — Shares due to
Teleflex under note hedge (C) — — — — — — — — $0.10 (3,366 )
Adjusted basis $215.7 $130.6 $13.4 — $12.8 — $15.5 $63.5 $1.42
44,715
Quarter Ended – June 29, 2014
Cost ofgoodssold
Selling,general
andadministrativeexpenses
Researchanddevelopmentexpenses
Restructuringand
otherimpairmentcharges
Interestexpense,net
Loss onextinguishmentof
debt, net
Incometaxes
Net
income(loss)attributableto
commonshareholdersfromcontinuingoperations
Dilutedearnings
pershareavailable
tocommonshareholders
Shares
usedincalculationof GAAP
andadjustedearnings pershare
GAAP Basis $224.0 $146.8 $14.9 $7.6 $15.9 — $10.0 $48.4 $1.04
46,392 Adjustments Restructuring and other impairment charges — — —
7.6 — — 3.5 4.2 $0.09 — Losses and other charges (A) 0.9 (1.1 ) 0.1
— — — — (0.2 ) — — Amortization of debt discount on convertible
notes — — — — 3.0 — 1.1 1.9 $0.04 — Intangible amortization expense
— 16.1 — — — — 4.4 11.7 $0.25 — Loss on extinguishment of debt, net
— — — — — — — — — — Tax adjustment (B) — — — — — — — — — — Shares
due to Teleflex under note hedge (C) — — — — — — — — $0.09 (2,714 )
Adjusted basis $223.1 $131.9 $14.8 — $12.9 — $19.0 $65.9 $1.51
43,678
(A) In 2015, losses and other charges include approximately $2.0
million, net of tax, or $0.04 per share, related to acquisition and
integration costs, and charges related to facility consolidations;
reversals included approximately ($2.7) million, net of tax, or
($0.06) per share, related to contingent consideration liabilities;
and approximately ($0.2) million, net of tax, or ($0.01) per share,
related to a litigation verdict against the Company with respect to
a non-operating joint venture. In 2014, losses and other charges
include approximately $4.2 million, net of tax, or $0.09 per share,
related to acquisition and integration costs; reversals included
approximately ($4.4) million, net of tax, or ($0.09) per share,
related to the reversal of contingent consideration
liabilities.
(B) The tax adjustment represents a net benefit resulting from
the resolution of, or the expiration of statute of limitations with
respect to various prior years’ U.S. federal, state and foreign tax
matters.
(C) Adjusted diluted shares are calculated by giving effect to
the anti-dilutive impact of the Company’s convertible note hedge
agreements, which reduce the potential economic dilution that
otherwise would occur upon conversion of our senior subordinated
convertible notes. Under GAAP, the anti-dilutive impact of the
convertible note hedge agreements is not reflected in diluted
shares.
RECONCILIATION
OF CONSOLIDATED STATEMENT OF INCOME ITEMS Dollars in
millions, except per share amounts Year-to-date Ended
– June 28, 2015
Cost ofgoodssold
Selling,general
andadministrativeexpenses
Researchanddevelopmentexpenses
Restructuringand
otherimpairmentcharges
Interestexpense,net
Loss onextinguishmentof
debt, net
Incometaxes
Net
income(loss)attributableto
commonshareholdersfromcontinuingoperations
Dilutedearnings
pershareavailable
tocommonshareholders
Shares
usedincalculationof GAAP
andadjustedearnings pershare
GAAP Basis $425.6 $281.9 $26.3 $5.0 $33.1 $10.5 $14.6 $83.8 $1.76
47,688 Adjustments Restructuring and other impairment charges — — —
5.0 — — 1.8 3.2 $0.07 — Losses and other charges (A) 5.2 (2.5 ) — —
— — 1.4 1.3 $0.02 — Amortization of debt discount on convertible
notes — — — — 6.5 — 2.4 4.1 $0.09 — Intangible amortization expense
— 29.8 — — — — 7.9 21.9 $0.46 — Loss on extinguishment of debt, net
— — — — — 10.5 3.8 6.6 $0.14 — Tax adjustment (B) — — — — — — 0.2
(0.2 ) — — Shares due to Teleflex under note hedge (C) — — — — — —
— — $0.19 (3,211 ) Adjusted basis $420.4 $254.6 $26.3 — $26.6 —
$32.1 $120.8 $2.72 44,477
Year-to-date Ended –
June 29, 2014
Cost ofgoodssold
Selling,general
andadministrativeexpenses
Researchanddevelopmentexpenses
Restructuringand
otherimpairmentcharges
Interestexpense,net
Loss onextinguishmentof
debt, net
Incometaxes
Net
income(loss)attributableto
commonshareholdersfromcontinuingoperations
Dilutedearnings
pershareavailable
tocommonshareholders
Shares
usedincalculationof GAAP
andadjustedearnings pershare
GAAP Basis $441.4 $287.1 $28.9 $15.4 $31.1 — $18.5 $83.5 $1.81
46,071 Adjustments Restructuring and other impairment charges — — —
15.4 — — 4.5 10.9 $0.24 — Losses and other charges (A) 0.9 (1.2 )
0.1 — — — 0.8 (1.1 ) ($0.03 ) — Amortization of debt discount on
convertible notes — — — — 6.0 — 2.2 3.8 $0.08 — Intangible
amortization expense — 32.1 — — — — 9.9 22.2 $0.48 — Loss on
extinguishment of debt, net — — — — — — — — — — Tax adjustment (B)
— — — — — — 0.2 (0.2 ) ($0.01 ) — Shares due to Teleflex under note
hedge (C) — — — — — — — — $0.15 (2,582 ) Adjusted basis $440.5
$256.3 $28.9 — $25.1 — $36.3 $118.9 $2.73 43,489
(A) In 2015, losses and other charges include approximately $3.9
million, net of tax, or $0.08 per share, related to acquisition and
integration costs, and charges related to facility consolidations;
reversals included approximately ($2.4) million, net of tax, or
($0.05) per share, related to contingent consideration liabilities;
and approximately ($0.2) million, net of tax, or ($0.01) per share,
related to a litigation verdict against the Company with respect to
a non-operating joint venture. In 2014, losses and other charges
include approximately $5.6 million, net of tax, or $0.12 per share,
related to acquisition and integration costs; reversals included
approximately ($6.7) million, net of tax, or ($0.15) per share,
related to the reversal of contingent consideration
liabilities.
(B) The tax adjustment represents a net benefit resulting from
the resolution of, or the expiration of statute of limitations with
respect to various prior years’ U.S. federal, state and foreign tax
matters.
(C) Adjusted diluted shares are calculated by giving effect to
the anti-dilutive impact of the Company’s convertible note hedge
agreements, which reduce the potential economic dilution that
otherwise would occur upon conversion of our senior subordinated
convertible notes. Under GAAP, the anti-dilutive impact of the
convertible note hedge agreements is not reflected in diluted
shares.
RECONCILIATION OF NET DEBT
OBLIGATIONS
June 28, 2015
December 31, 2014
(Dollars in thousands) Note payable and current portion of
long term borrowings $ 415,991 $ 368,401 Long term
borrowings 696,000 700,000 Unamortized debt discount 29,726
36,197 Total debt obligations 1,141,717 1,104,598
Less: cash and cash equivalents 325,010 303,236 Net debt
obligations $ 816,707 $ 801,362
ABOUT TELEFLEX INCORPORATED
Teleflex is a leading global provider of specialty medical
devices for a range of procedures in critical care and surgery. Our
mission is to provide solutions that enable healthcare providers to
improve outcomes and enhance patient and provider safety.
Headquartered in Wayne, PA, Teleflex employs approximately 12,400
people and serves healthcare providers worldwide. For additional
information about Teleflex please refer to www.teleflex.com.
CAUTION CONCERNING FORWARD-LOOKING INFORMATION
This press release contains forward-looking statements,
including, but not limited to, forecasted 2015 GAAP and constant
currency revenue growth and GAAP and adjusted diluted earnings per
share. Actual results could differ materially from those in the
forward-looking statements due to, among other things, conditions
in the end markets we serve, customer reaction to new products and
programs, our ability to achieve sales growth, price increases or
cost reductions; changes in the reimbursement practices of third
party payors; our ability to realize efficiencies and to execute on
our strategic initiatives; changes in material costs and
surcharges; market acceptance and unanticipated difficulties in
connection with the introduction of new products and product line
extensions; product recalls; unanticipated difficulties in
connection with the consolidation of manufacturing and
administrative functions, including as a result of difficulties
with various employees, labor representatives or regulators; the
loss of skilled employees in connection with such initiatives;
unanticipated difficulties, expenditures and delays in complying
with government regulations applicable to our businesses; the
impact of government healthcare reform legislation; our ability to
meet our debt obligations; changes in general and international
economic conditions, including fluctuations in foreign currency
exchange rates; and other factors described or incorporated in our
filings with the Securities and Exchange Commission, including our
Annual Report on Form 10-K for the year ended December 31,
2014.
TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited) Three Months Ended Six Months
Ended June 28, 2015 June 29, 2014 June
28, 2015 June 29, 2014 (Dollars and shares in
thousands, except per share) Net revenues $ 452,045 $ 468,105 $
881,475 $ 906,651 Cost of goods sold 218,808 224,017
425,601 441,404 Gross profit 233,237 244,088 455,874
465,247 Selling, general and administrative expenses 142,228
146,843 281,925 287,140 Research and development expenses 13,443
14,870 26,327 28,932 Restructuring and impairment charges 580
7,623 5,028 15,403 Income from
continuing operations before interest, extinguishment of debt and
taxes 76,986 74,752 142,594 133,772 Interest expense 16,207 16,062
33,379 31,466 Interest income (154 ) (146 ) (323 ) (333 ) Loss on
extinguishment of debt 10,454 — 10,454 —
Income from continuing operations before taxes 50,479 58,836
99,084 102,639 Taxes on income from continuing operations 5,280
10,006 14,612 18,540 Income from
continuing operations 45,199 48,830 84,472
84,099 Operating loss from discontinued operations (145 )
(1,594 ) (644 ) (1,619 ) Taxes (benefit) on loss from discontinued
operations 45 (469 ) 249 (369 ) Loss from
discontinued operations (190 ) (1,125 ) (893 ) (1,250 ) Net income
45,009 47,705 83,579 82,849
Less: Income from continuing operations
attributable to noncontrolling interest
446 453 664 639 Net income attributable
to common shareholders $ 44,563 $ 47,252 $ 82,915
$ 82,210 Earnings per share available to common
shareholders: Basic: Income from continuing operations $ 1.08 $
1.17 $ 2.02 $ 2.02 Loss from discontinued operations (0.01 ) (0.03
) (0.02 ) (0.03 ) Net income $ 1.07 $ 1.14 $ 2.00
$ 1.99 Diluted: Income from continuing operations $
0.93 $ 1.04 $ 1.76 $ 1.81 Loss from discontinued operations —
(0.02 ) (0.02 ) (0.03 ) Net income $ 0.93 $ 1.02
$ 1.74 $ 1.78 Dividends per share $ 0.34 $
0.34 $ 0.68 $ 0.68 Weighted average common shares outstanding Basic
41,560 41,380 41,514 41,321 Diluted 48,081 46,392 47,688 46,071
Amounts attributable to common shareholders: Income from continuing
operations, net of tax $ 44,753 $ 48,377 $ 83,808 $ 83,460 Loss
from discontinued operations, net of tax (190 ) (1,125 ) (893 )
(1,250 ) Net income $ 44,563 $ 47,252 $ 82,915
$ 82,210
TELEFLEX INCORPORATED AND
SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited) June 28, 2015 December
31, 2014 (Dollars in thousands) ASSETS Current
assets Cash and cash equivalents $ 325,010 $ 303,236 Accounts
receivable, net 286,371 273,704 Inventories, net 347,095 335,593
Prepaid expenses and other current assets 34,659 35,697 Prepaid
taxes 46,008 40,256 Deferred tax assets 56,294 57,301 Assets held
for sale 7,072 7,422 Total current assets 1,102,509 1,053,209
Property, plant and equipment, net 315,536 317,435 Goodwill
1,317,874 1,323,553 Intangible assets, net 1,185,517 1,216,720
Investments in affiliates 401 1,150 Deferred tax assets 1,134 1,178
Other assets 61,191 64,010 Total assets $ 3,984,162 $ 3,977,255
LIABILITIES AND EQUITY Current liabilities Current
borrowings $ 415,991 $ 368,401 Accounts payable 74,364 64,100
Accrued expenses 65,843 72,383 Current portion of contingent
consideration 5,802 11,276 Payroll and benefit-related liabilities
69,564 85,442 Accrued interest 7,991 9,169 Income taxes payable
11,700 13,768 Other current liabilities 10,631 10,360 Total current
liabilities 661,886 634,899 Long-term borrowings 696,000 700,000
Deferred tax liabilities 433,257 451,541 Pension and postretirement
benefit liabilities 161,036 167,241 Noncurrent liability for
uncertain tax provisions 50,547 50,884 Other liabilities 61,429
58,991 Total liabilities 2,064,155 2,063,556 Commitments and
contingencies Total common shareholders' equity 1,917,779 1,911,309
Noncontrolling interest 2,228 2,390 Total equity 1,920,007
1,913,699 Total liabilities and equity $ 3,984,162 $ 3,977,255
TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited) Six Months Ended June 28,
2015 June 29, 2014 (Dollars in thousands)
Cash Flows from Operating Activities of Continuing Operations Net
income $ 83,579 $ 82,849 Adjustments to reconcile net income to net
cash provided by operating activities: Loss from discontinued
operations 893 1,250 Depreciation expense 22,385 23,997
Amortization expense of intangible assets 29,826 32,102
Amortization expense of deferred financing costs and debt discount
8,421 7,716 Loss on extinguishment of debt 10,454 — Changes in
contingent consideration (2,293 ) (6,617 ) Stock-based compensation
7,126 5,726 Deferred income taxes, net 625 2,811 Other (6,301 )
(2,142 ) Changes in operating assets and liabilities, net of
effects of acquisitions and disposals: Accounts receivable (17,984
) 640 Inventories (16,895 ) (16,385 ) Prepaid expenses and other
current assets 921 2,407 Accounts payable and accrued expenses
(2,966 ) (1,731 ) Income taxes receivable and payable, net (8,203 )
(12,462 ) Net cash provided by operating activities from continuing
operations 109,588 120,161 Cash Flows from Investing
Activities of Continuing Operations: Expenditures for property,
plant and equipment (31,321 ) (30,850 ) Proceeds from sale of
assets and investments — 4,139 Payments for businesses and
intangibles acquired, net of cash acquired (37,559 ) (28,535 )
Investment in affiliates — (60 ) Net cash used in investing
activities from continuing operations (68,880 ) (55,306 ) Cash
Flows from Financing Activities of Continuing Operations: Proceeds
from new borrowings 288,100 250,000 Reduction in borrowings
(250,981 ) (480,000 ) Debt extinguishment, issuance and amendment
fees (8,746 ) (3,275 ) Net proceeds from share based compensation
plans and the related tax impacts 4,843 2,391 Payments to
noncontrolling interest shareholders (832 ) (1,094 ) Payments for
contingent consideration (3,989 ) — Dividends (28,234 ) (28,093 )
Net cash provided by (used in) financing activities from continuing
operations 161 (260,071 ) Cash Flows from Discontinued
Operations: Net cash used in operating activities (1,363 ) (1,531 )
Net cash used in discontinued operations (1,363 ) (1,531 ) Effect
of exchange rate changes on cash and cash equivalents (17,732 )
2,145 Net increase (decrease) in cash and cash equivalents
21,774 (194,602 ) Cash and cash equivalents at the beginning of the
period 303,236 431,984 Cash and cash equivalents at
the end of the period $ 325,010 $ 237,382
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150730005053/en/
Teleflex IncorporatedJake ElguiczeTreasurer and Vice President
of Investor Relations610-948-2836
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024